{
  "docId": "019de071-7055-71be-8e36-ff3241c1e380",
  "docSlug": "06f5a1d0d7573c1d13069d999ff5f2e2",
  "documentTitle": "RenovoRx | IPO Presentation Deck | 29 slides",
  "authorId": "renovorx",
  "authorName": "RenovoRx",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 4,
  "pageCount": 29,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide serves as a high-level company summary, highlighting clinical status, mechanism of action, market size, and regulatory moat.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-7055-71be-8e36-ff3241c1e380/4",
  "deckHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380",
  "deckJsonHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380.json",
  "deckAnchorHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "Lead product candidate RenovoGem™ currently in Phase 3 trial; Intra-arterial gemcitabine delivered through FDA cleared RenovoCath® delivery system; Phase 1/2 and observational registry trial data has demonstrated efficacy signals; Phase 3 trial > 40% enrolled",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0704402b-8d29-4623-a60a-361f196eccae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.02,
        "y": 0.38
      },
      "kind": "list",
      "text": "Targeted Approach → less toxicity, better efficacy; Reduced systemic drug exposure; Higher local drug concentration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "168a5720-764b-4595-b32b-b75ff3c3fd0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.02,
        "y": 0.65
      },
      "kind": "list",
      "text": "Broadly applicable to locally advanced solid tumors; Initial indications: pancreatic cancer ($1B addressable market) and cholangiocarcinoma; Potential future indications include non-small cell lung cancer, uterine tumors, glioblastoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "207f376b-d3d1-4e18-ac8d-6757e4b06dca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.6,
        "x": 0.02,
        "y": 0.52
      },
      "kind": "list",
      "text": "Novel therapy platform: RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™); Compatible with multiple small molecule chemotherapy drugs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c685ecd3-1152-4af1-bead-9110b9dbaa50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.02,
        "y": 0.8
      },
      "kind": "list",
      "text": "RenovoTAMP platform → layers of market exclusivity (regulatory and IP); Orphan Drug Designation provides 7 years of market exclusivity; 7 US patents issued",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb951aff-5206-4005-8f50-24fddd6dcdc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "RenovoRx: A Late-Stage Clinical Biopharmaceutical Company Novel Therapy Platform to Treat Locally Advanced Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bd11926-c417-42b1-b928-c08c208fcaa4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "eeb5d12f-412a-4325-8fbd-2a39f305b6d7",
      "evidence": "Slides 4 and 28 present the executive summary and investment highlights",
      "position": 1,
      "objective": "Present the investment highlights and ask",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}